

Canaccord Genuity
Digital & Tech-Enabled
Health Snapshot

Q3 2023 Update



Table of Contents

A. Canaccord Genuity Digital & Tech-Enabled Health Credentials

B. Digital & Tech-Enabled Health Market Update

Appendix: Select Q3 2023¹ Transactions



Canaccord Genuity
Digital & Tech-Enabled
Health Credentials

Section A



Canaccord Genuity is a Premier Investment Bank for Growth Companies

Global and Integrated Full-Service Platform

Deep Digital & Tech-Enabled Health Expertise



Analytics & Intelligence

Clinical

Software



Behavioral Health



Management



& Navigation



Care Coordination Chronic Disease Management







Employer-Sponsored Health Next-Gen **Primary Care**





Patient Financial Engagement



Pharma Marketina



Software

Physician Enablement



RCM & Payments Intelliaence



Telemedicine & Virtual Care



Workforce Management

Investment Banking

- 230+ investment bankers globally
- Led or participated in 359 transactions, raising over \$17.5 billion in FY 2023
- Solely focused on growth stories
- Listing capabilities on 10 stock exchanges worldwide

Equity Research

- 80+ research professionals
- Broad industry coverage across core sectors
- 860+ companies covered
- Quest® online valuation tool with 95% global coverage

Sales and Trading

- Equities and fixed income
- 150+ sales and trading professionals
- 15+ fixed income professionals
- 3.000+ institutions covered
- Market making
 - 2,500+ companies









Rob Higham



Leading Mid-Market Digital & Tech-Enabled Health M&A Advisor

Dedicated M&A team with deep transaction experience across sectors and geographies

Digital & Tech-Enabled Health Sell-Side Advisory¹

Rank	Firm Name	Transactions 2018 – Sep'23
1	Canaccord Genuity	62
2	TripleTree	59
3	William Blair	51
4	Ziegler	31
5	Houlihan Lokey	29
6	Raymond James	23
7	Brentwood Capital	22
7	Piper Sandler	22
9	Healthcare Growth Partners	19

Healthcare Mid-Market Advisory Since 2010²

	<u> </u>	
Rank	Firm Name	Deal Count
1	Piper Sandler	149
2	Stifel	113
3	Canaccord Genuity	106
4	William Blair	81
5	TD Securities	66
6	Raymond James	47
7	Oppenheimer	34
8	Robert W Baird	23
9	Citizens	16

Select Healthcare Transactions

medicx Financial Advisor on sale to Optimize Rx Pending





MIROCULUS



🎞 TI Health

Financial Advisor







Healthcare Vertical Business to $M \sim M3$ July 2023













December 2022



















July 2021















August 2021

PeriGen









June 2021



"torchlight

December 2021







iodine May 2021

[💟] Halma April 2021

Source: Canaccord Genuity database

Source: Dealogic data since 2010 for Middle-Market Healthcare transaction activity, as of 9/30/23

Leading Global Underwriter Since 2022

Dedicated M&A team with deep transaction experience across sectors and geographies

- Leveraging our global capabilities, CG ranks as the leading global underwriter and one of the top global bookrunners since 2022
- Underwriter on 571 total financings; Bookrunner on 451
- Transactions across US, Canada, Australia, & UK platforms

Select CG Financings



A\$300.000.000 Follow-on Offering Joint Bookrunner October 2023



September 2023







September 2023



August 2023



£291,450,000 Initial Public Offering Joint Bookrunner July 2023



C\$28,750,000 Follow-on Offering Joint Bookrunner July 2023



A\$40,000,000 Follow-on Offering Joint Bookrunner July 2023



Follow-on Offering Sole Bookrunner June 2023



A\$160,000,000 Follow-on Offering Sole Bookrunner June 2023



May 2023

Global League Table (US-Focused Banks) Global Total **Bookrun** Total Bank Deals **Proceeds** Rank **Deals** (\$M) Canaccord Genuity 21,673.5 1 571 451 2 **JPMorgan** 486 472 246.538.8 3 Goldman Sachs 468 453 270.445.7 4 Morgan Stanley 430 415 234.541.2 5 **BofA Securities** 415 395 247,204.8 6 Citi 342 333 219,132.7 UBS 325 311 137,452.3 9 Jefferies 71.678.7 249 247 10 **Barclays** 228 217 128.010.4 **RBC Capital Markets** 225 85.019.6 11 178 12 Stifel 223 53.903.5 140 **HC Wainwright** 13 221 170 7,599.7 15 Raymond James & Associates 207 101 33,448.2 17 **BMO Capital Markets** 192 118 54,740.8 25 Maxim Group 138 119 3.875.7 26 Wells Fargo 128 114 75.203.4 34 AGP/Alliance Global Partners 109 101 2.858.8 24,263.1 34 Piper Sandler 109 90 Cantor Fitzgerald 41 99 75 12,875.1 42 Leerink Partners 98 93 23,192.2 46 Deutsche Bank 89 80 82.433.3 47 Truist Financial 87 74 38.182.4 50 Evercore 83 82 34.037.6 EF Hutton 56 77 74 3,146.3 56 **Roth Capital Partners** 77 8,443.3 41

70

20

25,264.5

Source: Dealogic as of 9/30/23

59

BTIG




Digital & Tech-Enabled Health Market Update

Section B



Share Performance and Valuation Summary



	Summary	Statistics				
	Share Perf	formance	EV / 2023E			
i	YTD 23	LTM ²	Revenue	EBITDA ³		
NASDAQ	27.3%	22.2%	N/A	N/A		
S&P 500	12.1%	16.6%	N/A	N/A		
Next-Gen Primary Care	8.1%	(33.8%)	1.2x	19.6x		
Virtual Care and Digital Health	5.3%	(12.2%)	1.9x	12.1x		
Pharma	1.9%	5.2%	5.8x	20.3x		
Employer	(1.3%)	(11.8%)	2.4x	12.2x		
Payor	(8.0%)	(30.1%)	2.0x	11.4x		
Provider	(15.1%)	(27.5%)	2.9x	14.4x		

Past performance is not a guarantee of future results. Index returns are unmanaged, and do not include the deduction of fees or other expenses are unmanaged. The properties of the properties

Commentary


- Factors such as high interest rates and lower valuations resulted in fewer deals through the first three quarters of 2023 compared to the first three quarters of 2022; however, the digital health M&A market is gaining momentum as evidenced by recent transactions such as Thoma Bravo's announced acquisition of NextGen Healthcare and the merger of Virgin Pulse and HealthComp
- Q3'23 was a challenging quarter for the broader Digital & Tech-Enabled Health market, notably with the Provider end market, as several companies lowered guidance due to various concerns around profitability, slower growth, lower bookings and continued vendor consolidation
- The Next-Gen Primary Care, Virtual Care and Digital Health and Pharma sectors ended Q3'23 with positive YTD stock performance, and despite the lower YTD stock performance of the Provider public peer group, M&A demand is growing in this particular sector with half of all the Digital & Tech-Enabled Health transactions in Q3'23 occurring within this group, with three disclosed transactions over \$1B enterprise value

- Year to date "YTD"
- Last twelve months "LTM"
- Earnings before interest, taxes, depreciation and amortization "EBITDA"
- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and
 includes companies based outside the United States "Nasdaq"
 - Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries "S&P 500" and the same of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries "S&P 500" and the same of the broad domestic economy through changes in the aggregate market value of 500 stocks.
- Driven by your success.

Source: S&P Capital IQ as of 9/30/23; Projections based off consensus analyst estimates

Next-Gen Primary Care Overview

Public Peer Group Performance



Announced	Target	Buyer / Lead Investor(s) ¹	Transaction Type	Value (M) ²	Target Description
Sep-23	Select Primary Care Centers of Cano Health	CenterWell	M&A	\$67	Operations associated with Cano Health's senior-focused primary care centers in Texas and Nevada
Aug-23	Population Health Associates and Managed Care Insurance Consultants	Nutex Health	M&A	N/D	Provide high-quality, coordinated care to managed care patients through a network of primary care physicians
Aug-23	TytoCare	Insight Partners	Capital Raise	\$49	Virtual care company enabling leading health plans and providers to deliver high-quality primary care from home
Aug-23	Cerner Workforce Health Solutions	Marathon Health	M&A	N/D	Offers onsite and near-site health clinics focused on providing employer-sponsored primary care
Jul-23	MCI Medical Clinics (Ontario)	WELL Health	M&A	\$5	Operator of multi-disciplinary primary care clinics based in Ontario, Canada

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 9/30/23;

Projections based off consensus analyst estimates

1. Selected investors


M&A Transaction Value represents Enterprise Value at announcements; \$ in millions –
 "M": Not disclosed values – "N/D"

The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – "Nasdaq"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries—"S&P 500" A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted

Virtual Care and Digital Health Overview

Public Peer Group Performance



Announced	Target	Buyer / Lead Investor(s) ¹	Transaction Type	Value (M) ²	Target Description
Sep-23	Vivante Health	Mercato Partners	Capital Raise	\$31	Offers personalized care plans and connects patients with a care team of dietitians and gastroenterologists
Sep-23	Summus Global	Danaher Corporation / Sator Grove	Capital Raise	\$20	Offers patients, employers, health plans and providers a virtual care platform focused on specialty care, including peer-to-peer solutions and access to a specialist network
Aug-23	Better Life Partners	aMoon / F-Prime Capital	Capital Raise	\$27	Provider of integrated medical and behavioral healthcare intended for people to heal from addiction
Jul-23	Dialogue Health Technologies	Sun Life Financial	M&A	\$255	Digital health and wellness platform with offerings spanning employee assistance programs, primary care and wellness services
Jul-23	KHealth	Cedars Sinai Hospital	Capital Raise	\$59	Offers an Al platform bringing clinical data and medical expertise together to assist users with treatments and diagnosis

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 9/30/23; Projections based off consensus analyst estimates

Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements

- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and
 includes companies based outside the United States "Nasdaq"
- Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries "S&P 500"

Driven by your success.

Pharma Overview

Public Peer Group Performance



Announced	Target	Buyer / Lead Investor(s) ¹	Transaction Type	Value (M) ²	Target Description
Sep-23	VersaTrial	Florence Healthcare	M&A	N/D	Offers a smart assistant platform that allows sponsors and CROs ³ to improve clinical trial speed and quality through real-time operational insights and communication
Aug-23	Danam Health	Artemis Strategic	M&A	\$200	Offers a mobile app that allows patients to manage prescriptions and provides price transparency for pharmaceutical products
Jul-23	Neuroscience Education Institute	HMP Global	M&A	N/D	Provides online and in-person continuing medical education, teaching tools and other resources for psychopharmacology and neurologic disorders
Jul-23	Devana Solutions	RealTime Software Solutions	M&A	N/D	Offers clinical trial software bridging the tech and data divide to enable real-time collaboration, connectivity and data sharing between on-site and decentralized teams
Jul-23	CorEvitas	Thermo Fisher Scientific	M&A	\$913	Provides regulatory-grade, real-world evidence for approved medical treatments

the left of the chart. Performance is market cap-weighted

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 9/30/23;

fees or other expenses.

Projections based off consensus analyst estimates

1. Selected investors

M&A Transaction Value represents Enterprise Value at announcements

Clinical research organizations – "CRO"


The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – "Nasdaq"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the

Driven by your success.

Employer Overview

Public Peer Group Performance



Announced	Target	Buyer / Lead Investor(s) ¹	Transaction Type	Value (M) ²	Target Description
Sep-23	Virgin Pulse	HealthComp	M&A	N/D	Provides a digital-first health, wellbeing and navigation platform for employers and members
Sep-23	MDSave	Tendo	M&A	N/D	Streamlines healthcare access and billing, connecting individuals and employers to providers with transparent pricing to minimize out-of-pocket costs
Sep-23	Midi Health	Google Ventures	Capital Raise	\$25	Developer of a healthcare platform intended to treat women with menopause and other health issues
Sep-23	Take Command Health	Edison Partners	Capital Raise	\$25	Provider of an end-to-end individual healthcare benefits platform for small and mid-market employers
Sep-23	Manifesto Health	ERPHealth	M&A	N/D	Offers a comprehensive, evidence-based peer support and behavioral health coaching platform

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 9/30/23; Projections based off consensus analyst estimates

Driven by your success.

Selected investors


M&A Transaction Value represents Enterprise Value at announcements

The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and
includes companies based outside the United States – "Nasdaq"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – "S&P 500"

Payor Overview

Public Peer Group Performance



Announced	Target	Buyer / Lead Investor(s) ¹	Transaction Type	Value (M) ²	Target Description
Sep-23	TalisPoint	Perspecta	M&A	N/D	Provider of workers' compensation directory and data management solutions
Sep-23	Sempre Health	Cencora Ventures / Echo Health Ventures	Capital Raise	\$20	Offers a behavior-based healthcare pricing platform intended to provide dynamic copay discounts to members
Aug-23	VBA	Spectrum Equity	Capital Raise	\$156	Developer of a claims and benefits platform to offer cloud-based core administrative processing solutions
Aug-23	Tabula Rasa HealthCare	ExactCare	M&A	\$568	Provides personalized care and pharmacy services, including medication management and tools for health entities to optimize utilization and improve patient health
Aug-23	Healthmap	WindRose Health Investors	Capital Raise	\$100	Serves payors and at-risk providers seeking value-based solutions for the high-risk kidney disease population

the left of the chart. Performance is market cap-weighted

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 9/30/23; Projections based off consensus analyst estimates

fees or other expenses.

Selected investors

M&A Transaction Value represents Enterprise Value at announcements


The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Stockincludes companies based outside the United States - "Nasdag"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the properties of the propbroad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries - "S&P 500" and the second properties of the second

A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to

Provider Overview

Public Peer Group Performance



Announced	Target	Buyer / Lead Investor(s) ¹	Transaction Type	Value (M) ²	Target Description
Sep-23	Briya	Team8 / Insight Partners / Amiti Ventures	Capital Raise	\$12	Offers a secure platform designed for healthcare organizations to share patient data efficiently, securely and compliantly
Sep-23	NextGen Healthcare	Thoma Bravo	M&A	\$1,843	Offers clinical care solutions, including enterprise EHR, financial solutions and patient engagement solutions
Sep-23	Integrated Practice Solutions	PracticeTek	M&A	N/D	Offers practice management and EHR software to providers in chiropractic, optometry, speech and other therapy markets
Aug-23	Syntellis	Roper Technologies	M&A	\$1,400	Provider of enterprise performance management software, data and intelligence solutions
Jul-23	Nextech Systems	TPG Capital	M&A	\$1,400	Provides comprehensive EHR and practice management software to specialty physician practices

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 9/30/23; Projections based off consensus analyst estimates

- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States "Nasdaq"
- Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries "S&P 500"

Driven by your success.

Selected investors

M&A Transaction Value represents Enterprise Value at announcements



Select Q3 2023 Transactions

Appendix



Select Q3'23 M&A Transactions

Ann.				Enterprise	EV/F	lev.	EV/Adj.	EBITDA
Date	Target	Acquiror	Sub-sector	Value (\$M)	LTM	NTM ¹	LTM	NTM ¹
Sep-23	Virgin Pulse	HealthComp	Employer	N/D	N/D	N/D	N/D	N/D
Sep-23	Select Assets of Cano Health	CenterWell	Next-Gen Primary Care	\$67	N/D	N/D	N/D	N/D
Sep-23	Healthjump	Datavant	Provider	N/D	N/D	N/D	N/D	N/D
Sep-23	MDSave	Tendo	Employer	N/D	N/D	N/D	N/D	N/D
Sep-23	VersaTrial	Florence Healthcare	Pharma	N/D	N/D	N/D	N/D	N/D
Sep-23	gWell	InformedDNA	Virtual Care and Digital Health	N/D	N/D	N/D	N/D	N/D
Sep-23	Fident Health	Avel eCare	Virtual Care and Digital Health	N/D	N/D	N/D	N/D	N/D
Sep-23	TalisPoint	Perspecta	Payor	N/D	N/D	N/D	N/D	N/D
Sep-23	KxAdvisors	BGB Group	Pharma	N/D	N/D	N/D	N/D	N/D
Sep-23	MedQIA	WorldCare Clinical	Pharma	N/D	N/D	N/D	N/D	N/D
Sep-23	NextGen Healthcare	Thoma Bravo	Provider	\$1,843	2.7x	2.6x	15.4x	14.5x
Sep-23	Therapy Direct	Enlyte	Payor	N/D	N/D	N/D	N/D	N/D
Sep-23	Manifesto Health	ERPHealth	Payor	N/D	N/D	N/D	N/D	N/D
Sep-23	Odeza Patient Engagement	TeleVox	Provider	N/D	N/D	N/D	N/D	N/D
Sep-23	Integrated Practice Solutions	PracticeTek	Provider	N/D	N/D	N/D	N/D	N/D
Sep-23	Bigfoot Biomedical	Abbott	Virtual Care and Digital Health	N/D	N/D	N/D	N/D	N/D
Sep-23	Vatica Health	Frazier Healthcare	Payor	N/D	N/D	N/D	N/D	N/D
Aug-23	Crowe's Healthcare Consulting	TPG	Provider	N/D	N/D	N/D	N/D	N/D
Aug-23	Access eForms	Phreesia	Provider	\$38	N/D	N/D	N/D	N/D
Aug-23	HealthPay24	Waystar	Provider	N/D	N/D	N/D	N/D	N/D
Aug-23	Experience Care	WellSky	Provider	N/D	N/D	N/D	N/D	N/D
Aug-23	PHA and MCIC	Nutex Health	Next-Gen Primary Care	N/D	N/D	N/D	N/D	N/D
Aug-23	QualityMetric	IQVIA	Pharma	N/D	N/D	N/D	N/D	N/D
Aug-23	Nuvo Group	LAMF Global	Provider	\$269	N/D	N/D	N/D	N/D

Source: Company filings and press releases

^{1.} Next twelve months – "NTM"

Select Q3'23 M&A Transactions (cont.)

DateTargetAcquirorSub-sectorValue (\$M)LTMNTMLTMAug-23AQREVA and Doctors' ResourceUnisLinkProviderN/DN/DN/DAug-23PopuliDefinitive HealthcareProvider\$52N/DN/DN/DAug-23Bamboo Medical CommunicationsAptitude HealthPharmaN/DN/DN/DN/DAug-23SyntellisRoper TechnologiesProvider\$1,400N/D7.6xN/DAug-23Danam HealthArtemis StrategicPharma\$200N/DN/DN/DAug-23Tabula Rasa HealthCareExactCarePayor\$5681.7x1.5x32.9xAug-23LuminelloSimplePracticeProviderN/DN/DN/DN/D	NTM N/D N/D 16.5x ¹ N/D 22.1x N/D
Aug-23 Populi Definitive Healthcare Provider \$52 N/D N/D N/D Aug-23 Bamboo Medical Communications Aptitude Health Pharma N/D N/D N/D N/D Aug-23 Syntellis Roper Technologies Provider \$1,400 N/D 7.6x N/D Aug-23 Danam Health Artemis Strategic Pharma \$200 N/D N/D N/D N/D Aug-23 Tabula Rasa HealthCare ExactCare Payor \$568 1.7x 1.5x 32.9x	N/D N/D 16.5x ¹ N/D 22.1x N/D
Aug-23Bamboo Medical CommunicationsAptitude HealthPharmaN/DN/DN/DN/DAug-23SyntellisRoper TechnologiesProvider\$1,400N/D7.6xN/DAug-23Danam HealthArtemis StrategicPharma\$200N/DN/DN/DAug-23Tabula Rasa Health CareExact CarePayor\$5681.7x1.5x32.9x	N/D 16.5x ¹ N/D 22.1x N/D
Aug-23SyntellisRoper TechnologiesProvider\$1,400N/D7.6xN/DAug-23Danam HealthArtemis StrategicPharma\$200N/DN/DN/DAug-23Tabula Rasa HealthCareExactCarePayor\$5681.7x1.5x32.9x	16.5x ¹ N/D 22.1x N/D
Aug-23Danam HealthArtemis StrategicPharma\$200N/DN/DN/DAug-23Tabula Rasa HealthCareExactCarePayor\$5681.7x1.5x32.9x	N/D 22.1x N/D
Aug-23 Tabula Rasa HealthCare ExactCare Payor \$568 1.7x 1.5x 32.9x	22.1x N/D
	N/D
Aug-23 Luminello SimplePractice Provider N/D N/D N/D N/D	
The state of the s	
Aug-23 eCatalyst Healthcare Solutions e4health Provider N/D N/D N/D N/D	N/D
Aug-23 Cerner Workforce Health Solutions Marathon Health Next-Gen Primary Care N/D N/D N/D N/D	N/D
Jul-23 Dialogue Health Technologies Sun Life Financial Virtual Care and Digital Health \$255 3.7x 2.5x NMF	NMF
Jul-23 Complia Health Axxess Provider N/D N/D N/D N/D	N/D
Jul-23 MCI Medical Clinics (Ontario) WELL Health Next-Gen Primary Care \$5 N/D 0.2x N/D	N/D
Jul-23 Nextech Systems TPG Capital Provider \$1,400 N/D N/D N/D	N/D
Jul-23 Medxoom Allied Benefit Systems Employer N/D N/D N/D N/D	N/D
Jul-23 Continuum Health Solutions Aspirion Provider N/D N/D N/D N/D	N/D
Jul-23MedifindPhreesiaProviderN/DN/DN/DN/D	N/D
Jul-23 Limbix Big Health Virtual Care and Digital Health N/D N/D N/D N/D	N/D
Jul-23 CarePlus Management WELL Health Provider N/D N/D N/D N/D	N/D
Jul-23 Neuroscience Education Institute HMP Global Pharma N/D N/D N/D N/D	N/D
Jul-23 Devana Solutions RealTime Software Pharma N/D N/D N/D N/D	N/D
Jul-23CorEvitasThermo Fisher ScientificPharma\$9138.3xN/DN/D	N/D
Jul-23 Somnoware ResMed Provider N/D N/D N/D N/D	N/D
Jul-23 Medacist Bluesight (Thoma Bravo) Pharma N/D N/D N/D N/D	N/D

^{1.} NTM EBITDA includes planned cost synergies

Disclosures

18

This material is provided for information purposes only and is intended for distribution in those jurisdictions where subsidiaries of Canaccord Genuity Group Inc. (together, "Canaccord Genuity") are registered as advisors or dealers in securities. Any distribution or dissemination of this material in any other jurisdiction is strictly prohibited. The information does not constitute an offer or solicitation in any jurisdiction in which such an offer or solicitation is not authorized, or to any person to whom it is unlawful to make such an offer or solicitation. This is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs to any person. Clients should obtain advice based on their own individual circumstances before making an investment decision. Any client wishing to effect any transactions should do so through a Canaccord Genuity qualified salesperson in their jurisdiction of residence.

The information contained herein has been compiled by Canaccord Genuity from sources believed to be reliable, but no representation or warranty, express or implied, is made by Canaccord Genuity or any other person to its fairness, accuracy, completeness or correctness. To the fullest extent permitted by law, neither Canaccord Genuity nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained herein.

All material presented in this document, unless specifically indicated otherwise, is under trademark and copyright to Canaccord Genuity. None of the material, or its content, or any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of Canaccord Genuity.

Note to Readers: This report was created by members of the investment banking department of Canaccord Genuity LLC ("Canaccord" or "Canaccord Genuity") and has not been reviewed by or discussed with any members of the Canaccord Genuity research department. This report is not intended to be, and in no way constitutes, a "research report," as such term is defined by Rule 137 promulgated under the Securities Act of 1933, as amended. Canaccord Genuity's investment banking department has done, and may continue to do, business with companies included in this report. This document is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. This report is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. This material is prepared for general circulation to corporate and institutional clients and does not have regard for the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, neither Canaccord Genuity, its affiliates nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained in this report. Past performance is not indicative of future results. Canaccord Genuity LLC is a registered broker-dealer regulated by the SEC and FINRA. Member SIPC. Offices in other countries are offices of other companies in the Canaccord group of companies. See https://www.canaccord.cont.nivestor-resources/contact-us/our-companies/ for more information.

Copyright © Canaccord Genuity Corp. 2023. – Member CIRO/Canadian Investor Protection Fund

Copyright © Canaccord Genuity Limited 2023. – Member of the London Stock Exchange, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2023. – Member FINRA/SIPC

Copyright @ Canaccord Genuity (Australia) Limited 2023. – Authorized and regulated by ASIC.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This document may contain certain "forward-looking information" (as defined under applicable securities laws). These statements relate to future events or future performance and include management's expectations, beliefs, plans, estimates, intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts, business and economic conditions and Canaccord Genuity Group LLC's (the "Company") growth, results of operations, market position, ability to compete and future financial or operating performance of the Company, performance and business prospects and opportunities. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue", "target", "intend", "could" or the negative of these terms or other comparable terminology. By its very nature, forward-looking information involves inherent risks and uncertainties, both general and specific, and a number of factors could cause actual events or results to differ materially from the results discussed in the forward-looking information. In evaluating these statements, readers should specifically consider various factors, which may cause actual results to differ materially from any forward-looking statement. These factors include, but are not limited to, market and general economic conditions, the nature of the financial services industry, the risks and uncertainties discussed from time to time in the Company's interim and annual consolidated financial statements and its Annual Information Form filed on www.sedar.com. Readers are cautioned that the preceding list of material factors or assumptions is not exhaustive. Except as may be required by applicable law, the Company does not und